natgillin/translations-raw huggingface dataset:
Pharmacokinetic drug interaction studies with Ristfor have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin.
Študije farmakokinetičnih interakcij z zdravilom Ristfor niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama, sitagliptinom in metforminom.
Pharmacokinetic drug interaction studies with Velmetia have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin.
Študije farmakokinetičnih interakcij z zdravilom Velmetia niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama, sitagliptinom in metforminom.
Pharmacokinetic drug interactions involving CYP450 are not expected (see section 5.2).
Farmakokinetične interakcije, povezane s CYP450, niso pričakovane (glejte poglavje 5.2).
Pharmacokinetic enhancement by ritonavir is based on ritonavir’s activity as a potent inhibitor of CYP3A- mediated metabolism.
Farmakokinetično stopnjevanje z ritonavirjem temelji na tem, da ritonavir močno zavira presnovo s CYP3A.
Pharmacokinetic enhancer
Farmakokinetični stopnjevalec
Pharmacokinetic enhancer and concomitant medications
Farmakokinetični ojačevalec in sočasna zdravila
pharmacokinetic enhancer should be with caution at reduced doses of no more than 10 mg tadalafil every 72 hours with increased monitoring for adverse reactions (see section 4.4).
Ob tem je potrebno intenzivnejše nadziranje glede neželenih učinkov (glejte poglavje 4.4).
Pharmacokinetic Enhancers
Farmakokinetični spodbujevalci
pharmacokinetic interaction
farmakokinetičnih interakcij.
pharmacokinetic interaction
Ni klinično pomembnih farmakokinetičnih interakcij.
Pharmacokinetic Interaction Data
Podatki o farmakokinetičnih interakcijah
Pharmacokinetic Interaction Data between the Individual Components of DUTREBIS and Other Medicinal Products
Podatki o farmakokinetičnih medsebojnih delovanjih obeh posameznih učinkovin zdravila DUTREBIS in drugih zdravil
Pharmacokinetic Interaction Data in Adults
Podatki o farmakokinetičnih interakcijah pri odraslih
Pharmacokinetic interactions
Farmakokinetična medsebojna delovanja z drugimi učinkovinami
Pharmacokinetic interactions may be observed with gastrointestinal prokinetic agents, such as cisapride and metoclopramide.
Farmakokinetično medsebojno delovanje lahko opazimo pri prokinetično delujočih učinkovinah z delovanjem na želodec in črevo, kot sta cisaprid in metoklopramid.
Pharmacokinetic modelling simulation analysis showed that Defitelio plasma concentrations do not accumulate upon multiple dose administration and with doses up to 4-fold the therapeutic dose.
Farmakokinetična analiza s simulacijo modela je pokazala, da se koncentracije zdravila Defitelio v plazmi pri uporabi večkratnih odmerkov, do 4-krat večjih od terapevtskega odmerka, ne kopičijo.
Pharmacokinetic parameter comparisons of pazopanib Cmax (range of means 27.5 to 58.1 µg/ml) and AUC(0-24) (range of means 48.7 to 1040 µg*h/ml) after administration of pazopanib 800 mg alone and after administration of pazopanib 400 mg plus ketoconazole 400 mg (mean Cmax 59.2 µg/ml, mean
Opravili so primerjave farmakokinetičnih parametrov pazopaniba Cmax (razpon povprečij od 27,5 do 58,1 µg/ml) in AUC(0-24) (razpon povprečij od 48,7 do 1040 µg*h/ml) po uporabi 800 mg pazopaniba samega in po uporabi 400 mg pazopaniba s 400 mg ketokonazola (povprečna Cmax 59,2 µg/ml, povprečna AUC(0-24) 1300 µg*h/ml).
Pharmacokinetic Parameter Estimates for BeneFIX (75 IU/kg) at Baseline and Month 6 in Previously Treated Patients with Haemophilia B
Ocene farmakokinetičnih parametrov za zdravilo BeneFIX (75 i.e./kg) v izhodišču in v 6. mesecu pri predhodno zdravljenih bolnikih s hemofilijo B
Pharmacokinetic parameters (mean (%CV))
Farmakokinetični parametri (povprečje (%VK))
Pharmacokinetic parameters and the extent of absorption have not been studied in children.
Farmakokinetični parametrov in obsega absorpcije niso preučili pri otrocih.
Pharmacokinetic parameters at week 1 as a function of body weight in studies TKT024 and HGT-ELA-038
Farmakokinetični parametri v 1. tednu študij TKT024 in HGT-ELA-038 v odvisnosti od telesne mase
Pharmacokinetic parameters for bivalirudin in patients with normal and impaired renal function
Farmakokinetični parametri za bivalirudin pri bolnikih z normalno in okvarjeno ledvično funkcijo.
Pharmacokinetic parameters in Caelyx-treated AIDS-KS patients
Farmakokinetični parametri zdravila Caelyx pri bolnikih s Kaposijevim sarkomom, povezanim z aidsom
Pharmacokinetic parameters of DepoCyte (75 mg) in neoplastic meningitis patients in whom the medicinal product was administered either intraventricularly or by lumbar puncture suggest that exposure to the active substance in the ventricular or lumbar spaces is similar regardless of the route of administration.
Farmakokinetični paramteri zdravila DepoCyte (75 mg) pri bolnikih z neoplastičnim meningitisom, katerim so zdravilo dajali intraventrikularno ali z lumbalno punkcijo, kažejo, da je izpostavljenost zdravilni učinkovini v ventrikularnih ali lumbalnih prostorih podobna, ne glede na način uporabe.
Pharmacokinetic Parameters of HyQvia Compared to Intravenous Administration of IG 10%
Farmakokinetični parametri zdravila HyQvia v primerjavi z intravenskim dajanjem IG 10
Pharmacokinetic parameters of Privigen in PID patients
Farmakokinetični parametri zdravila Privigen pri bolnikih s PID
Pharmacokinetic parameters of the non-compartmental analysis after 50 IU/kg dose of ALPROLIX are presented in Table 5
Farmakokinetični parametri neprostorske analize po odmerku 50 i.e./kg zdravila ALPROLIX so predstavljeni v preglednici 3.
Pharmacokinetic parameters such as clearance, distribution volume, and elimination half-life were comparable for both formulations.
Farmakokinetični parametri, npr. očistek, volumen porazdelitve in razpolovni čas izločanja zdravila, so bili pri obeh oblikah podobni.
Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600 mg/m2 mycophenolate mofetil orally twice daily.
Farmakokinetične parametre so opazovali pri 49 otrocih in mladostnikih z ledvičnim presadkom (starih od 2 do 18 let), ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan.
Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18°years) given 600°mg/m2 mycophenolate mofetil orally twice daily.
Farmakokinetične parametre so opazovali pri 49 otrocih in mladostnikih z ledvičnim presadkom (starih od 2 do 18 let), ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan.
Pharmacokinetic parameters were mainly determined following administration of single doses of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected subjects with varying degrees of renal impairment.
Farmakokinetične parametre so v glavnem določili po vzetju enkratnih odmerkov 200 mg emtricitabina ali 245 mg dizoproksiltenofovirata pri bolnikih, ki niso bili okuženi s HIV, z različnimi stopnjami ledvične okvare.
Pharmacokinetic parameters1
Farmakokinetični parametri1
Pharmacokinetic particulars
Farmakokinetične podatki
Pharmacokinetic particulars
Farmakokinetične posebnosti
Pharmacokinetic particulars Dogs
Farmakokinetične posebnosti Psi:
Pharmacokinetic properties
5.3 Farmakokinetične lastnosti
Pharmacokinetic properties
Farmakokineticne lastnosti
Pharmacokinetic properties
Farmakokinetične posebnosti
Pharmacokinetic properties
Farmakokinetični podatki
Pharmacokinetic properties
Lyfjahvörf
Pharmacokinetic properties Absorption
Farmakokinetične lastnosti Absorpcija
Pharmacokinetic properties Absorption
Farmakokinetični podatki Absorpcija
Pharmacokinetic properties Absorption, distribution and elimination
Farmakokinetične lastnosti Absorpcija, porazdelitev in izločanje
Pharmacokinetic properties are similar in CAPS and SJIA paediatric populations.
Farmakokinetične lastnosti zdravila so v populacijah pediatričnih bolnikov s CAPS oziroma SJIA podobne.
Pharmacokinetic properties for aztreonam for injection
Farmakokinetične lastnosti aztreonama za injiciranje
Pharmacokinetic properties of ReFacto, derived from a cross-over study of ReFacto and a plasma- derived FVIII concentrate, using the chromogenic substrate assay (see section 4.2), in 18 previously treated patients are listed in the table below.
Farmakokinetične lastnosti zdravila ReFacto, pridobljene iz navzkrižne študije zdravila ReFacto in koncentrata FVIII, pridobljenega iz plazme, z uporabo preskusa s kromogenim substratom (glejte poglavje 4.2) pri 18 predhodno zdravljenih bolnikih, so navedene v spodnji preglednici.
Pharmacokinetic properties were evaluated in 22 subjects (≥19 years) receiving ALPROLIX (rFIXFc).
Farmakokinetične lastnosti so ocenili pri 22 osebah (≥ 19 let), ki so dobivale zdravilo ALPROLIX (rFIXFc).
Pharmacokinetic properties were evaluated in 28 subjects (≥ 15 years) receiving ELOCTA (rFVIIIFc).
Farmakokinetične lastnosti so ocenili pri 28 osebah (≥ 15 let), ki so dobivale zdravilo ELOCTA (rFVIIIFc).
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 800/100 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum
Rezultati farmakokinetike celokupnega darunavirja po jemanju zdravil darunavir/ritonavirv odmerkih 800/100 mg enkrat na dan kot del protiretrovirusnega zdravljenja med drugim in tretjim trimesečjem nosečnosti ter v obdobju po porodu
Pharmacokinetic simulations indicate that the overall exposure (AUC0-) of 0.25 mg intravenous palonosetron administered once daily for 3 consecutive days was similar to a single intravenous dose of 0.75 mg, although Cmax of the 0.75 mg single dose was higher.
Farmakokinetične simulacije kažejo, da je bila celotna izpostavljenost (AUC0-) po 0,25 mg intravenskega palonosetrona, dajanega enkrat na dan 3 zaporedne dni, podobna kot po enkratnem intravenskem odmerku 0,75 mg, čeprav je bila Cmax enkratnega odmerka 0,75 mg višja.
Pharmacokinetic studies for CE/bazedoxifene were conducted in healthy postmenopausal women who were naturally postmenopausal or who had undergone bilateral oophorectomy.
Farmakokinetične študije kombinacije CE/bazedoksifena so izvedli pri zdravih ženskah v postmenopavzi, ki so bile naravno v postmenopavzi ali pa so imele bilateralno ooforektomijo.
Pharmacokinetic studies have included subjects and patients from different ethnic groups, and no differences in the typical exposure to tadalafil have been identified.
Farmakokinetične študije so vključevale osebe in bolnike različnih etničnih skupin; opazili niso nobenih razlik v biološki uporabnosti tadalafila.
Pharmacokinetic studies have not been conducted in paediatric or older subjects.
Farmakokinetičnih študij pri otrocih in starejših ljudeh niso opravili.
Pharmacokinetic studies have not been performed in children under the age of 12 years.
Pri otrocih, mlajših od 12 let, niso opravili farmakokinetičnih študij.
Pharmacokinetic studies have not been performed in the elderly (over 65 years of age).
Farmakokinetične študije niso bile izvedene pri starejših (nad 65 let).
Pharmacokinetic studies have not been performed with emtricitabine or tenofovir in the elderly (over 65 years of age).
Farmakokinetične študije z emtricitabinom ali tenofovirjem niso bile izvedene pri starostnikih (nad 65 let).
Pharmacokinetic studies have not been performed with Senshio in the paediatric population.
Z zdravilom Senshio niso izvajali farmakokinetičnih študij pri pediatrični populaciji.
Pharmacokinetic studies have not been performed with tenofovir disoproxil (as fumarate) 245 mg tablets in children under 12 years or with renal impairment.
Farmakokinetične študije s 245 mg tabletami dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) niso bile izvedene pri otrocih, mlajših kot 12 let, ali tistih z ledvično okvaro.
Pharmacokinetic studies have not been performed with tenofovir disoproxil (as fumarate) in children under 2 years.
Farmakokinetične študije z dizoproksiltenofoviratom (v obliki fumarata) niso bile izvedene pri otrocih, mlajših od 2 let.
Pharmacokinetic studies have not been performed with tenofovir disoproxil in children under 2 years.
Farmakokinetične študije z dizoproksiltenofoviratom niso bile izvedene pri otrocih, mlajših od 2 let.
Pharmacokinetic studies in humans showed that the plasma concentration curve of cladribine fits a 2- or 3-compartment model with - and β-half-lives of on average 35 minutes and 6.7 hours, respectively.
Farmakokinetične študije pri človeku so pokazale, da krivulja plazemske koncentracije kladribina ustreza modelu z 2 ali 3 razdelki z - in β-razpolovnimi časi povprečno 35 minut oziroma 6,7 ur.
Pharmacokinetic studies indicate that imepitoin is well absorbed (> 92 %) after oral administration and that no pronounced first pass effect occurs.
Farmakokinetične študije nakazujejo, da se imepitoin dobro absorbira (> 92 %) po peroralnem dajanju in da se ne pojavi izrazit učinek presnove prvega prehoda.
Pharmacokinetic studies indicate that the range and frequency of detection of quantifiable 9-cis- retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis-retinoic acid in untreated individuals (see section 5.2).
S farmakokinetičnimi raziskavami so ugotovili, da sta obseg in pogostost odkritja merljive koncentracije 9-cis-retinoidne kisline v plazmi pri KS bolnikih po nanosu zdravila primerljivi z obsegom in pogostostjo merljive koncentracije 9-cis-retinoidne kisline v obtoku v plazmi, ki se naravno pojavi pri nezdravljenih posameznikih (glejte poglavje 5.2).
Pharmacokinetic studies performed with radio-labelled mirabegron have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7-fold higher than plasma levels at 4 hours post administration (see section 4.6).
Farmakokinetične študije z radioaktivno označenim mirabegronom so pokazale, da se matična spojina in/ali njeni presnovki izločajo v mleku podgan v koncentraciji, ki je pribliţno 1,7-krat večja od koncentracije v plazmi 4 ure po uporabi (glejte poglavje 4.6).
Pharmacokinetic studies performed with radio-labelled ticagrelor have shown that the parent compound and its metabolites are excreted in the milk of rats (see section 4.6).
Farmakokinetične študije z radioaktivno označenim ticagrelorjem so pokazale, da se matična spojina in njeni presnovki izločajo v mleku podgan (glejte poglavje 4.6).
Pharmacokinetic variability was higher in the moderate hepatic impairment group (co-efficient of variation in systemic exposure [AUCinf] was 50% versus <30% in the other hepatic function groups).
V skupini z zmerno okvaro jeter je bila variabilnost farmakokinetike večja (koeficient variacije sistemske izpostavljenosti [AUCinf] je znašal 50 % v primerjavi z < 30 % v skupinah z drugačnim delovanjem jeter).
Pharmacokinetic, biodistribution and dosimetry data were obtained in 6 patients at an activity of 110 kBq/kg given twice, 6 weeks apart, and in 10 patients at an activity of 55, 110 or 221 kBq/kg.
Farmakokinetične podatke, podatke o biološki porazdelitvi in dozimetriji so pridobili pri 6 bolnikih z aktivnostmi 110 kBq/kg, apliciranih dvakrat v časovnem razmaku 6 tednov in pri 10 bolnikih z aktivnostmi 55, 110 ali 221 kBq/kg.
Pharmacokinetic/Pharmacodynamic (PK/PD) relationship
Farmakokinetično/farmakodinamično (FK/FD) razmerje
Pharmacokinetic/Pharmacodynamic (PK/PD) relationship:
Razmerje med farmakokinetiko in farmakodinamiko (FK/FD):
Pharmacokinetic/pharmacodynamic relationship
Razmerje med farmakokinetiko in farmakodinamiko
Pharmacokinetic/pharmacodynamic relationship:
Farmakokinetično/farmakodinamična povezava:
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the (CSF) levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetično/farmakodinamična povezava: Pri odmerku 20 mg memantina na dan so vrednosti v likvorju skladne s ki vrednostjo (ki = konstanta inhibicije) memantina, ki je 0,5 µmol v frontalnem korteksu pri človeku.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetično/farmakodinamična povezava: Pri odmerku 20 mg memantina na dan so vrednosti v CSL skladne s ki vrednostjo (ki = konstanta inhibicije) memantina, ki je 0,5 µmol v frontalnem korteksu pri človeku.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetično/farmakodinamična povezava: Pri odmerku 20 mg memantina na dan so vrednosti v likvorju skladne s ki vrednostjo (ki = konstanta inhibicije) memantina, ki je 0,5 µmol v frontalnem korteksu pri človeku.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki= inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Farmakokinetično/farmakodinamična povezava: Pri odmerku 20 mg memantina na dan so vrednosti v likvorju skladne s ki vrednostjo (ki = konstanta inhibicije) memantina, ki je 0,5 µmol v frontalnem korteksu pri človeku.
Pharmacokinetic/pharmacodynamic relationships:
Farmakokinetično/farmakodinamično razmerje
Pharmacokinetics determined with a population approach in patients with erectile dysfunction is similar to pharmacokinetics in subjects without erectile dysfunction.
Farmakokinetika, ugotovljena s populacijskim pristopom pri bolnikih z erektilno disfunkcijo, je podobna farmakokinetiki pri osebah brez erektilne disfunkcije.
Pharmacokinetics has not been specifically studied in the elderly.
Farmakokinetike pri starostnikih niso posebej preučevali.
Pharmacokinetics has not been specifically studied in the hepatic disease patients.
Farmakokinetike pri bolnikih z boleznimi jeter niso posebej preučevali.
Pharmacokinetics has not been specifically studied in the renal disease patients.
Farmakokinetike pri bolnikih z boleznimi ledvic niso posebej preučevali.
Pharmacokinetics have not been specifically studied in different ethnic groups.
Farmakokinetike niso posebej preučevali pri različnih etničnih skupinah.
Pharmacokinetics in elderly patients have not been investigated.
Farmakokinetike pri starejših bolnikih niso preučevali.
Pharmacokinetics in paediatric population
Farmakokinetika pri pediatrični populaciji
Pharmacokinetics in pregnancy
Farmakokinetika med nosečnostjo
Pharmacokinetics in special patient groups Elderly:
Farmakokinetika pri posebnih skupinah bolnikov Starejši:
Pharmacokinetics in special populations e.g. elderly/renal impairment etc.
Farmakokinetika pri posebnih populacijah, npr. starejših bolnikih/ledvični okvari
Pharmacokinetics in specialpopulations:
Farmakokinetika pri posebnih populacijah:
Pharmacokinetics in subpopulations
Farmakokinetika v podpopulacijah
Pharmacokinetics in the paediatric population have not been studied.
Farmakokinetika pri pediatrični populaciji ni bila raziskana.
Pharmacokinetics in the paediatric population have not been studied.
Farmakokinetika pri pediatrični populaciji ni raziskana.
Pharmacokinetics is nonlinear with the area under the plasma concentration curve (AUC) versus time curve increasing 3.8-fold as dose is doubled from 4.5 g to 9 g.
Farmakokinetika je nelinearna; površina pod krivuljo plazemske koncentracije (AUC) v odvisnosti od časa se po podvojitvi odmerka iz 4,5 g na 9 g poveča za 3,8-krat.
Pharmacokinetics observed in patients with rheumatoid arthritis were consistent with those seen in healthy subjects.
Farmakokinetične lastnosti, ki so jih opažali pri bolnikih z revmatoidnim artritisom, so bile skladne s farmakokinetiko zdravih oseb.
Pharmacokinetics of 5-ALA in patients with renal or liver impairment has not been investigated.
Farmakokinetike 5-ALA pri bolnikih z ledvično ali jetrno okvaro niso raziskovali.
Pharmacokinetics of asfotase alfa were evaluated in a 1-month, multicenter, open-label, dose- escalating, study in adults with hypophosphatasia.
Farmakokinetiko asfotaze alfa so ocenili v 1-mesečni, multicentrični, odprti študiji z večanjem odmerka pri odraslih s hipofosfatazijo.
Pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate have not been fully evaluated in hepatitis B and/or C virus co-infected patients.
Farmakokinetične lastnosti emtricitabina in dizoproksiltenofovirijevega fumarata pri bolnikih s sočasno okužbo z virusom hepatitisa B in/ali C niso v celoti ovrednotili.
Pharmacokinetics of etravirine (mean ± SD, median)
Farmakokinetika etravirina (povprečna ± SD, mediana)
Pharmacokinetics of fesoterodine in patients with severe hepatic impairment have not been studied.
Farmakokinetike fesoterodina pri bolnikih s hudo okvaro jeter niso preiskovali.
Pharmacokinetics of imatinib
Farmakokinetika zdravila Imatinib Actavis
Pharmacokinetics of indinavir do not appear to be affected by race.
Ni videti, da bi rasa vplivala na farmakokinetiko indinavirja.
Pharmacokinetics of NovoSeven in patients with Glanzmann’s thrombasthenia have not been investigated, but are expected to be similar to the pharmacokinetics in haemophilia A and B patients.
Farmakokinetika zdravila NovoSeven pri bolnikih z Glanzmannovo trombastenijo ni raziskana, vendar je mogoče pričakovati, da je podobna farmakokinetiki pri bolnikih s hemofilijo A in B.
Pharmacokinetics of obinutuzumab in patients with mild creatinine clearance (CrCl 50-89 mL/min, n=464) or moderate (CrCl 30 to 49 mL/min, n=106) renal impairment were similar to those in patients with normal renal function (CrCl  90 mL/min, n=383).
Farmakokinetika obinutuzumaba je bila pri bolnikih z blago (očistek kreatinina 50–89 ml/min, n = 464) ali zmerno (očistek kreatinina 30–49 ml/min, n = 106) ledvično okvaro podobna kot pri bolnikih z normalnim delovanjem ledvic (očistek kreatinina  90 ml/min, n = 383).
Pharmacokinetics of pixantrone proved to be linear in a broad range of doses, from 3 mg/m2 to 105 mg/m2.
Farmakokinetika piksantrona je bila linearna v širokem razponu odmerkov od 3 mg/m2 do 105 mg/m2.
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30 - < 50 ml/min/1.73m2) and healthy subjects.
Farmakokinetika prasugrela in njegovo zaviranje agregacije trombocitov sta podobna pri bolnikih z zmerno okvaro ledvic (GFR 30 < 50 ml/min/1,73 m2) in zdravih osebah.
Pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
Farmakokinetika telmisartana se med starejšimi bolniki in bolniki, mlajšimi od 65 let, ne razlikuje.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in subjects with mild (CrCl: 60 to 89 ml/min), moderate (CrCl: 30 to 59 ml/min) and severe (CrCl: 15 to 29 ml/min) renal impairment, relative to subjects with normal renal function.
Farmakokinetiko kombinacije 25 mg ombitasvirja, 150 mg paritaprevirja in 100 mg ritonavirja (s 400 mg dasabuvirja) so ocenili pri preiskovancih z blago (očistek kreatinina od 60 do 89 ml/min), zmerno (očistek kreatinina od 30 do 59 ml/min) in hudo (očistek kreatinina od 15 do 29 ml/min) okvaro ledvic glede na preiskovance z normalnim delovanjem ledvic.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg were not evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child- Pugh C) hepatic impairment.
Farmakokinetike kombinacije 25 mg ombitasvirja, 200 mg paritaprevirja in 100 mg ritonavirja niso ocenili pri preiskovancih z blago (Child-Pugh A), zmerno (Child-Pugh B) in hudo (Child-Pugh C) okvaro jeter.